Clinical implications of the interaction between metabolic risk factors, coronary artery disease and atrial fibrillation
- 13 December 2025
- journal article
- Published by Taylor & Francis in Future Cardiology
- Vol. 22 (1) , 57-63
Abstract
Atrial fibrillation (AF) and coronary artery disease (CAD) frequently coexist due to shared risk factors such as obesity and diabetes. The interrelationship between these diseases carries important therapeutic implications, given the fact that both AF and CAD are associated with an increased risk for cardiovascular events such as stroke, myocardial infarction, heart failure and cardiovascular mortality. In this review, we elucidate our current understanding of the epidemiological and pathophysiological links between AF and CAD, with particular focus on the impact of obesity, diabetes and systemic inflammation as common drivers. We discuss the implications for patient management, including antithrombotic therapy, lifestyle modifications and metabolic risk reduction. Beyond antithrombotic therapy, we highlight the importance of rate and rhythm control strategies in case of coexisting of AF and CAD. Novel pharmacological approaches for patients with CAD and type 2 diabetes, such as GLP-1 receptor agonist and SGLT2 inhibitors, provide additional cardiometabolic benefits by reducing the risk of major adverse cardiovascular events. Finally we propose a framework for integrated management of AF and CAD that aligns with contemporary guidelines and emerging evidence. This holistic approach, including metabolic risk factor modification, represents a paradigm shift in the care of patients with both AF and CAD.Keywords
This publication has 69 references indexed in Scilit:
- Interactions of Obstructive Sleep Apnea With the Pathophysiology of Cardiovascular Disease, Part 1JACC, 2024
- Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW TrialJACC, 2024
- Rate control or rhythm control in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary interventionHeliyon, 2024
- Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐PreservedJournal of Cachexia, Sarcopenia and Muscle, 2023
- Patients with atrial fibrillation and coronary artery disease – Double troubleAdvances in Medical Sciences, 2018
- Body mass index, abdominal fatness, fat mass and the risk of atrial fibrillation: a systematic review and dose–response meta-analysis of prospective studiesEuropean Journal of Epidemiology, 2017
- How to get a smoker addicted to quittingNetherlands Heart Journal, 2016
- Prevalence and Implications of Subclinical Coronary Artery Disease in Patients With Atrial FibrillationThe American Journal of Cardiology, 2015
- An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)American Heart Journal, 2015
- Atrial Fibrillation and the Risk of Myocardial InfarctionJAMA Internal Medicine, 2014